PT - JOURNAL ARTICLE AU - Higashizono, Kazuya AU - Nakatani, Eiji AU - Hawke, Philip AU - Fujimoto, Shuhei AU - Oba, Noriyuki TI - Risk factors for gallstone disease onset in Japan: findings from the Shizuoka Study, a population-based cohort study AID - 10.1101/2022.09.02.22279528 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.02.22279528 4099 - http://medrxiv.org/content/early/2022/09/02/2022.09.02.22279528.short 4100 - http://medrxiv.org/content/early/2022/09/02/2022.09.02.22279528.full AB - In the research literature on factors associated with gallstones, large population-based cohort studies are rare. We carried out a study of this type to explore risk factors for the onset of gallstones. This study included Japanese participants aged 40-107 years who were followed prospectively from January 2012 to September 2020 using a dataset composed of two individually linked databases, one containing annual health checkup records and the other containing medical claims for beneficiaries of the National Health Insurance System and the Medical Care System for Elderly in the Latter Stage of Life in Shizuoka Prefecture, Japan. Among the 611,930 participants in the analysis set, 23,843 (3.9%) were diagnosed with gallstones during the observational period (median [max]: 5.68 [7.5] years). Multivariate analysis revealed that risk of gallstone disease was increased by male sex, cerebrovascular disease, any malignancy, dementia, rheumatic disease, chronic pulmonary disease, hypertension, and H. pylori-infected gastritis. These findings provide essential insights into the etiology of cholelithiasis and may contribute to efforts to reduce the incidence of the disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Shizuoka Graduate University of Public Health conducts research projects on public health under contract to Shizuoka Prefecture, including this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All enrollee data was anonymized by the Federation of National Health Insurance Association to protect participant confidentiality. This study adhered to the principles of the Declaration of Helsinki and was approved by the Medical Ethics Committee of Shizuoka Graduate School of Public Health in Shizuoka, Japan (#SGUPH_2021_001_040).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesBased on a data use agreement with regional insurers in Shizuoka Prefecture, we are unable to make the analytical data accessible to readers.